Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1239-1247

  Goldstein, Matthew J ^a   Kohrt, Holbrook E ^a   Houot, Roch ^a   Varghese, Bindu ^a   Lin, Jack T ^a   Swanson, Erica ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; HERMES ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD137; ANTIGENS, CD44; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY;

EID: 84863229631     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3375     Document Type: Article

References (28)

1. Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009;113:85-94.
2. + T cells that are effective in adoptive therapy for large and established tumors. Blood 2011;117:118-27.
3. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4. (Pubitemid 35231542)
4. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57. (Pubitemid 46218728)
5. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R,Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
6. + T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J Immunother 2001;24: 323-33.
7. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007;179: 2493-500.
8. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703. (Pubitemid 351860862)
9. +) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
10. +) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010;207:651-67.
11. +) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
12. Smith KS, Rhee JW, Cleary ML. Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol Cell Biol 2002;22:7678-87.
13. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008;14:335-43.
14. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000;192:549-56. (Pubitemid 30666255)
15. + T cells. Nat Immunol 2006;7:475-81.
16. McKinstry KK, Strutt TM, Swain SL. The effector to memory transition of CD4 T cells. Immunol Res 2008;40:114-27. (Pubitemid 351912833)
17. +memory stem cells. Nat Med 2009;15:808-13.
18. +memory stem cells in graft-versus-host disease. Nat Med 2005;11: 1299-305.
19. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL. Multilayered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 2008;29:383-90.
20. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106. (Pubitemid 46160986)
21. Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008; 14:6895-906.
22. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114: 3431-8.
23. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
24. +) regulatory T cells that are expanded at tumor sites. J Immunol 2010;184:6545-51.
25. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005;115:1953-62. (Pubitemid 40979735)
26. + Tregs. Clin Immunol 2008;126:291-302.
27. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006;176: 4622-31.
28. + regulatory T cells in human thymus and periphery. Immunity 2008;28:870-80.